Centinel Spine (CNTL) files S-1 for NYSE IPO with a heavyweight underwriting team
As seen on the 24/7 Wall St. homepage on October 7, 2026.
Centinel Spine files for NYSE IPO
Spinal disc replacement maker Centinel Spine filed its S-1 to list on the NYSE, lining up Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity and BTIG to run the deal, an underwriting bench that signals how big this one is meant to be. Terms and pricing are still to come.
Continue ReadingShow less
Centinel Spine Holdco, Inc. has registered its S-1 with the SEC, taking the first formal step toward a public listing on the NYSE. The company makes spinal disc replacement devices, competing in a corner of the orthopedic market drawing investor attention as surgeons and patients push for motion-preserving alternatives to spinal fusion.
The underwriting lineup assembled for this deal is notable on its own: Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity, and BTIG are all signed on to run the offering. A five-bank bench of that caliber, anchored by two of Wall Street's largest equity underwriters, is typically reserved for deals with meaningful size and institutional demand ambitions.
Pricing terms and the number of shares to be offered have not yet been disclosed, which is standard at the S-1 registration stage. Those details will emerge in subsequent amendments to the filing as the company and its bankers gauge investor appetite during the roadshow process.
For investors watching the medtech IPO calendar, Centinel Spine is now one to track closely. The gap between registration and pricing can close quickly once bookbuilding begins in earnest.